vTv Therapeutics Inc (VTVT)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$21.74-9.53%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · VTVT
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Worth watching into the next print: this name has erratic recent earnings surprises and is a smaller-cap name (higher miss base rate). A fundamental tilt, not a price call.
Model as of 2026-11-04 · Compared with 66 industry peers
VTVT — earnings miss
Dated 2026-08-06
Results of Operations and Financial Condition On August 6, 2026, vTv Therapeutics Inc. issued a press release to announce its financial results for the fiscal period ended June 30, 2026. A copy of the press release is attached as Exhibit 99.1 to this current report on Form 8-K and is incorporated herein by reference. The information in this report (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18, of the Securities Exchange Act of 1934, as amended (the “Exc…
Why it matters: Finishing enrollment keeps the Phase 3 trial on its stated path toward topline results.
Supportive ifThe company confirms CATT1 enrollment was done by September 30, 2026.
Worry ifThe company says enrollment was not done by September 30, 2026, or gives a later target.
Why it matters: Management says cash can fund operations through the data readout. Cash fell from $98.1 million in Q1 to $86.6 million in Q2.
Worry ifA later company update reports cash below $86.6 million and says funds may not last through CATT1 topline data.
Less concerning ifThe next report shows cash of at least $86.6 million, or confirms funds remain enough to reach the topline readout.
Why it matters: This report can confirm trial timing and cash runway after the Q2 update. It is the next dated company event in the calendar.
Watch forThe November 5 report confirms CATT1 enrollment is done. Cash still covers operations through topline data.
Also watch forThe November 5 report says enrollment is delayed, or cash may not last through topline data.
Why it matters: The result will test whether cadisegliatin can help people with type 1 diabetes. It is the main data event named by management.
Watch forThe readout reports that CATT1 met its stated primary endpoint, as defined in the trial report.
Also watch forThe readout says CATT1 missed its stated main goal, or found a safety issue that limits use.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$169 on $10,000 · ±1.7% | How much price usually moves either way. |
| Bad day | $690 loss on $10,000 · 6.9% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $4,487 loss on $10,000 · 44.9% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.